BIOGEN INC. is 4.5x more valuable than Kymera Therapeutics, Inc. by market capitalization ($28.73 B vs $6.44 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KYMR | BIIB |
|---|---|---|
| Market cap | $6.44 B | $28.73 B |
| US-listed rank | #1211 | #479 |
| Revenue (latest FY) | $39.21M | $9.89B |
| Net income (latest FY) | $311.35M | $1.29B |
| Net margin | 794.0% | 13.1% |
| P/E (trailing FY) | 20.7 | 22.2 |
| SEC filings | 575 | 2,690 |
BIOGEN INC. is 4.5x more valuable than Kymera Therapeutics, Inc. by market capitalization ($28.73 B vs $6.44 B).
In their latest fiscal years, Kymera Therapeutics, Inc. reported $39.21M in revenue while BIOGEN INC. reported $9.89B.
Full pages: Kymera Therapeutics, Inc. and BIOGEN INC., or browse the full rankings.